This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prober, C. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prober, C. G.
Related Collections
Right arrow Office Practice

PEDIATRICS Vol. 106 No. 6 December 2000, p. e89

ELECTRONIC ARTICLE:
Technical Report: Precautions Regarding the Use of Aerosolized Antibiotics

Charles G. Prober, Philip D. Walson, Jim Jones, and the Committee on Infectious Diseases and Committee on Drugs

In 1998, the Food and Drug Administration (FDA) approved the licensure of tobramycin solution for inhalation (TOBI). Although a number of additional antibiotics, including other aminoglycosides, beta -lactams, antibiotics in the polymyxin class, and vancomycin, have been administered as aerosols for many years, none are approved by the FDA for administration by inhalation.

TOBI was approved by the FDA for the maintenance therapy of patients 6 years or older with cystic fibrosis (CF) who have between 25% and 75% of predicted forced expiratory volume in 1 second (FEV1), are colonized with Pseudomonas aeruginosa, and are able to comply with the prescribed medical regimen. TOBI was not approved for the therapy of acute pulmonary exacerbations in patients with CF nor was it approved for use in patients without CF. Currently, no other antibiotics are approved for administration by inhalation to patients with or without CF.

The purpose of this statement is to briefly summarize the data that supported approval for licensure of TOBI and to provide recommendations for its safe use. The pharmacokinetics of inhaled aminoglycosides and problems associated with aerosolized antibiotic treatment, including environmental contamination, selection of resistant microbes, and airway exposure to excipients in intravenous formulations, will be discussed.

 Key words:  aerosolized antibiotics, tobramycin solution for inhalation, cystic fibrosis, Pseudomonas aeruginosa.


Statements of reaffirmation:

AAP Publications Retired and Reaffirmed

Pediatrics 114: 1126-1126. [Full Text]

AAP Publications Retired or Reaffirmed
Pediatrics 121: 647-647. [Full Text]



This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
E. Foglia, M. D. Meier, and A. Elward
Ventilator-Associated Pneumonia in Neonatal and Pediatric Intensive Care Unit Patients
Clin. Microbiol. Rev., July 1, 2007; 20(3): 409 - 425.
[Abstract] [Full Text] [PDF]